Share this article
ALBANY, N.Y., April 19, 2021 /PRNewswire/
Osteoporosis has a high health and economic burden. This is especially due to the fact that the condition remains asymptomatic and largely gets detected only when individuals suffer with frequent fractures. The prevalence is high in women, and poses high morbidity and even mortality in aging women. Osteoporosis leads to osteopenia and osteoporosis in adulthood, and leads to high risk of skeletal fractures, both in women and men. An array of therapeutic agents are being explored for developing drugs of choice for the target population. This has propelled the evolution of the osteoporosis drugs market. Major drug class comprise bisphosphonates, Calcitonin, RANK ligand inhibitors, parathyroid hormone therapy, and selective estrogen receptor modulators (SERMs).Of these, bisphosphonates and RANK ligand inhibitors have been highly lucrative segments, due to substantive prescriptions. The underlying genetics, pathogenesis, a